Palatin (PTN) Commends FDA Vote in Favor of Flibanserin Approval in HSDD

UPDATE: Palatin Technologies' (PTN) Price Target Raised to $6 at Canaccord Genuity Amid Flibanserin FDA Panel Backing

(Updated - June 5, 2015 8:41 AM EDT)

Canaccord Genuity analyst John Newman reiterated a Buy rating and boosted his price target on Palatin Technologies (NYSE: PTN) to $6.00 (from $4.00) after an FDA advisory committee approves Flibanserin with safety reservation.

Newman commented, "The FDA advisory committee voted 18-6 in favor of approving Flibanserin,... More

Positive FDA Committee Vote on Flibanserin Bodes Well for Palatin's (PTN) Bremelanotide - Roth Capital

Roth Capital reaffirms its Buy rating and $4 price target on Palatin Technologies (NYSE: PTN) following news that Sprout Pharmaceuticals received a majority positive vote at its FDA Advisory Committee meeting for flibanserin in female sexual dysfunction (FSD).

Analyst Joseph Pantginis commented, We believe that todays positive AdCom opinion for flibanserin, potentially the first FDA approved treatment for FSD, bodes well for PTN's BMT. Flibanserin... More

Palatin (PTN) Advances After FDA Panel Backs Sprout's Female Libido Drug

Palatin Technologies (NYSE: PTN) advanced Thursday on news an FDA panel voted to support approval of Sprout's female libido drug. Notably, Palatin's Bremelanotide is in advanced trials to treat female sexual dysfunction.